ArticleFrontiers in oncology2025
Diagnostic performance of a radiological Fagotti score assessed on diffusion-weighted magnetic resonance imaging for predicting tumor resectability in ovarian cancer patients: a feasibility study.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: In ovarian cancer, the correct selection of patients for cytoreductive surgery is of great importance. The aim of this study was to evaluate the diagnostic performance of the Fagotti score assessed on preoperative diffusion-weighted magnetic resonance imaging (DW-MRI) for predicting tumor resectability in patients with ovarian cancer. Methods: This retrospective cohort study included patients with ovarian cancer who underwent surgical treatment between 2014 and 2022 at University Hospital Bern, Switzerland. All patients had a preoperative MRI performed. The surgical and MRI Fagotti scores were assessed retrospectively, and follow-up data were available through standardized databases and follow-up controls. Results: A total of 52 imaging studies in 50 patients met the inclusion criteria. The majority of the patients presented with primary diagnosis (73.1%), serous histological subtype (75.0%), and advanced International Federation of Gynecology and Obstetrics (FIGO) stage (76.9%). The mean surgical Fagotti score was 3.4 (±3.24), while the mean MRI Fagotti score was 2.8 (±2.92). Consistency between the surgical and MRI assessments was 94.2% for stomach infiltration, 80.8% for superficial liver metastasis, and 80.8% for peritoneal, 80.8% for mesenteric, 78.8% for small bowel, 75.0% for omental, and 65.4% for diaphragmatic involvement. An MRI Fagotti score of <8 predicted a no residual disease (R0) resection with a sensitivity of 97.4%, a positive predictive value of 86.0%, and a negative predictive value of 83.3%. Patients with an MRI Fagotti score of <6 showed a significantly longer recurrence-free survival (log-rank, Conclusion: According to the study results, the assessment of the Fagotti score on preoperative imaging with DW-MRI is feasible and useful in predicting tumor resectability in patients with ovarian cancer. Furthermore, an MRI Fagotti score higher than 6 is associated with worse oncological outcomes. However, further studies on a larger patient population are needed to confirm our results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.